I
n the last 10 years, annual national health expenditures in the United States have increased by over $1 trillion 1 and now account for over 17% of the gross domestic product. 2 Although health expenditures per capita in the United States are more than twice those of many other developed nations, 3 the United States fails to provide better quality health care or achieve better health outcomes than other countries. Recognizing this disparity and the shortcomings of our current system, the United States Department of Health and Human Services is now prioritizing efforts (i.e., alternative payment models) that incentivize high-quality and low-cost health care. 4, 5 In light of these changes, 6 there is a clear and present need to identify populations that could benefit from targeted efforts to impact health care cost, quality, and outcomes.
Pediatric inflammatory bowel disease (IBD) is a chronic medical condition whose economic burden deserves attention, as incidence rates are consistently growing worldwide and the condition is increasingly viewed as an emerging global epidemic. [7] [8] [9] The annual national burden of pediatric IBD from hospitalizations alone is estimated to be $152.4 million, 10 and because hospitalizations make up only one-third of costs for IBD, 11 the total annual costs for pediatric IBD may be over $450 million. As with many chronic conditions, there is significant patient-level variability in clinical and economic outcomes. [11] [12] [13] Specifically, per patient annual costs range from under $100 to tens of thousands of dollars, 10, 11 and patients may be adequately maintained on mesalamine or immunomodulators, or they may progress rapidly to more costly biologic therapies and surgery if remission is not sustained. Given this substantial cost, it is critical that we identify modifiable predictors of health care costs to target through prevention and intervention efforts to reduce costs and service utilization. In addition, because lifelong patterns of disease management are established in childhood and adolescence, 14 efforts to identify and target predictors of health outcomes in this demographic may improve the clinical course of chronic conditions across the lifespan.
A modifiable factor that may account for differences in health outcomes and health care costs is nonadherence to treatment recommendations. Among children with a chronic medical condition, nonadherence is related to increased health care use. 15 In adults with IBD, patients who are nonadherent to infliximab incur significantly higher direct medical costs compared with those who are adherent. [16] [17] [18] [19] Nonadherence to oral medications also impacts costs, with patients who are adherent to mesalamine incurring 12.5% lower annual medical care costs, 62% lower hospital admission costs, 45% lower emergency department visit costs, and 13% lower outpatient visit costs compared with those who are nonadherent. 20 This study, however, categorized patients as adherent or nonadherent using a cut point of 80% rather than measuring adherence continuously, which limits the implications of the results as the clinically meaningful cut point at which nonadherence significantly impacts clinical outcomes and health care utilization is not established and is likely to vary across medications. 21 Nonadherence may lead to increased health care costs through several pathways. First, patients who are nonadherent to medications are more likely to experience increased symptoms or complications that require medical attention. [22] [23] [24] [25] [26] [27] Nonadherence may also result in a poor treatment response and escalation of therapy. For example, patients with IBD may be advanced to potentially avoidable and costly biologics or surgery without their physician having the benefit of knowing the patients' adherence to oral medication therapy. Addressing the issue of nonadherence in this scenario would have substantial cost savings as patients maintained on oral medication therapy in IBD incur approximately $3600 annually, those maintained on biologics incur $25,000 to $40,000 annually, and surgery can cost $50,000 or more depending on several factors. 28, 29 There is a critical need to determine the relationship between nonadherence and health care costs in pediatric IBD because children and adolescents (i.e., younger than 20 years) have more frequent hospitalizations, emergency department visits, and outpatient visits than adults with IBD 12 and have medical costs in the highest quartile 11, 12 or 17% to 105% higher than their adult counterparts. 11 Given their age, they are also more likely to incur significantly greater health care costs across the lifespan compared with adults. Answering this question, however, requires a statistical approach that accounts for the variability in nonadherence within and across patients over time. Using statistical techniques that compare costs across patients who demonstrate different patterns of nonadherence will help determine who cost-minimization adherence-promotion efforts should target and the optimal timing of such interventions. Thus, we conducted this longitudinal cohort study to advance the understanding of the complex relationship between nonadherence and health care costs while accounting for the impact of disease activity. We accomplished this by analyzing trajectories of nonadherence (as opposed to classifications of nonadherence) over the study period along with concurrent disease status and hospital charges billed for health care services (referred to in this article as "health care costs"). We hypothesized that at least 3 distinct trajectories (i.e., stable, increasing, and decreasing) of nonadherence would be found and that patients in the increasing nonadherence group would account for significantly greater health care costs after controlling for the effects of disease activity.
PATIENTS AND METHODS

Study Design and Sample
This was a longitudinal, retrospective, observational, cohort study of adherence, disease activity, and health care costs. Data were collected retrospectively to prevent any adherence behavior change in participants who would have resulted from being monitored prospectively. Measures of nonadherence, disease severity, and health care costs were collected for each patient at monthly intervals over the 2-year period.
Patients between ages 2 and 21 years with a diagnosis of ulcerative colitis, Crohn's disease, or indeterminate colitis were recruited from the IBD Center at Cincinnati Children's Hospital Medical Center (CCHMC). Additional eligibility criteria included the following: the prescription of an immunomodulator (i.e., 6-MP/azathioprine) and aminosalicylates and at least 1 outpatient IBD Center visit per year over a contiguous 2-year period.
Measures
Nonadherence
Monthly adherence percentage for each patient was calculated using a medication possession ratio (MPR). To create equal time intervals, we calculated approximately 26 "months" in the 2-year study period using 28 days as the proxy for 1 month. The monthly MPR is calculated using the formula: ð number of daily doses dispensed per 28 days 28 Þ · 100. Values were capped so that the range was 0 to 100. As the duration of medication prescriptions can vary (e.g., 30-180 days), measuring monthly adherence standardizes the unit of time between outcome measures for all patients. For any cases in which more than 1 month supply was dispensed, nonadherence was simply carried forward. For example, if a patient is dispensed a 3-month supply, month 3 data would reveal the nonadherence from months 1 and 2 as well as 3. For patients prescribed multiple medications during a 28-day period or whose prescribed medications changed, an overall monthly MPR was created averaging all adherence values (including both immunomodulators and aminosalicylates) for that month. An overall monthly MPR was used instead of multiple adherence values as it is not possible to attribute health care charges to a specific medication. The overall monthly MPR was then subtracted from 100 to convert this value to a measure of nonadherence (e.g., MPR ¼ 70%, nonadherence ¼ 30%). To evaluate the potential impact of patients not using their home medication supply while hospitalized and, thus, appearing to be more nonadherent, we reviewed each medical chart to determine the proportion of hospitalized days for the sample during the course of the study. Over the entire sample, patients were hospitalized for only 0.34% of the total number of days in the study. Given this extremely low percentage, the potential impact is negligible and nonadherence values were not adjusted for days hospitalized.
Disease Severity
Standard care in the IBD Center includes routine assessment of disease severity through Physician Global Assessment (PGA) in which physicians rate patient disease activity as "quiescent," "mild," "moderate," or "severe." This approach correlates well with objective measures of disease severity in IBD including the Pediatric Crohn's Disease Activity Index (PCDAI) 30 and Peditric Ulcerative Colitis Activity Index (PUCAI). 31 Disease severity at each month was defined as the most recent previous PGA rating. Patients with missing PGA data (n ¼ 4) were excluded from the analyses.
Health Care Charges
Health care charges were used as a proxy for the value of health care services over the 2-year period. In reference to data in this study, "health care costs" is used to describe charges. All hospital and physician charges associated with an International Classification of Diseases, Ninth Revision code for ulcerative colitis (556.x) or Crohn's disease (550.x) were obtained from the hospital's accounting database for the 2-year period. Any charges for biologic therapies were excluded to focus analyses on oral medication adherence and charges. Monthly health care charges were calculated using a gross costing approach by summing all charges for hospital and physician services within the 28-day period at the patient level. Monthly health care charges were then adjusted to 2014 US dollars according to the medical care component of the consumer price index. 32 The outcome variable, total hospital charges over the 2-year period, was then computed by summing all adjusted monthly charges for each patient.
Procedures
Disease severity, demographic, and clinical variables were obtained through medical record review. Patient pharmacy refill records were obtained from patient/family identified pharmacies to calculate MPR and nonadherence percent. Hospital billing records were used to calculate health care charges. Approval for study procedures was obtained from the institutional review board. Patients and caregivers provided informed consent/assent before data collection.
Data Analyses
Analyses were performed in 2 steps. First, latent class growth mixture modeling (LCGMM) analyses were performed using SAS (Version 9.3) PROC TRAJ to identify unobserved subgroups of patients with similar longitudinal disease severity (PGA) and medication nonadherence data. In contrast to a multiple-group longitudinal model, where an observed variable (i.e., sex, ethnicity, intravenous group designation, etc.) is expected to explain a portion of the response variable variance over time, LCGMM assumes that the response variable variation over time has resulted from the presence of 2 or more unobserved subgroups in the dataset. LCGMM classifies participants within 1 of the 2 or more subgroups based on similarities of response variable scores over time. Each of the subgroups, thus, has its own unique average response variable change trajectory.
LCGMM analyses were performed first to determine whether k $ 2 unobserved subgroups (heterogeneity) or a single group (k ¼ 1; homogeneity) generated the PGA and nonadherence sample data. The number of distinct subgroups that generated the sample data was determined by examining the following: (1) model parameter estimation convergence, (2) longitudinal trend component (i.e., linear slope, quadratic change, cubic change, etc.) statistical significance within the k subgroup classes, (3) minimized repeated-measures residual variance estimates (s 2 ) and a minimized model fit statistic (Bayesian information criterion) values for a given k-subgroup classes versus k + 1 subgroup classes solutions, both indicative of a better fit of a k -subgroup class model versus a k + 1 subgroup class model to the sample data, and (4) posterior probabilities for a k-subgroup solution that showed greater certainty in classifying individual participants to classes compared with a k + 1 subgroup solution.
The possibility of k ¼ 1 to 5 subgroup class solutions were examined, and k-subgroup solutions in which one of the classes comprising 5% or less of the participants in the sample data were discarded. The k subgroup solutions were then cross-tabulated to determine the number of individuals in each k disease severity class present within each of the k classes of nonadherence. Second, descriptive statistics were used to examine the hypothesis that total charges differed across PGA and nonadherence subgroups. Means, SDs, and 95% confidence intervals (CIs) for total charges were computed for each of the k subgroups. Subgroups with nonoverlapping 95% CIs were considered to have significantly different total charges at P , 0.05 by definition. Effect sizes representing the magnitude of differences between subgroups were also calculated using Cohen's d.
RESULTS
Descriptive statistics were conducted on demographic and disease parameters to describe relevant sample characteristics including age, sex, race, specific IBD diagnosis, and type of medication. Table 1 illustrates these descriptive data.
Trajectory Analyses
LCGMM results revealed that k ¼ 4 subgroups best modeled the longitudinal variation in both disease severity and nonadherence.
The 4 disease severity subgroups are described as follows: (1) an increasing disease severity group (n ¼ 16), (2) a stable low disease severity group (n ¼ 51), (3) a decreasing disease severity group (n ¼ 25), and (4) a varying disease severity group (n ¼ 10). Similarly, the 4 nonadherence groups (Fig. 1) are described as follows: (1) an increasing (i.e., worsening) nonadherence group (n ¼ 14), (2) a stable #10% nonadherence group (n ¼ 18), (3) a decreasing (i.e., improving) nonadherence group (n ¼ 21), and (4) a stable 11% to 20% nonadherence group (n ¼ 46). Because our focus in this study was on health care costs associated with nonadherence, only nonadherence subgroup trajectories and associated cost data are depicted.
Effect sizes were calculated to determine significant differences in costs between disease severity subgroups and nonadherence subgroups. These analyses demonstrated that total health care costs did not differ across disease severity subgroups. An average total costs d ¼ 0.68 effect size was observed between the increasing severity (95% CI, $28,978.17-$151,028.76) and stable low severity groups (95% CI, $21,577.62-$56,044.19), but the 95% CIs for their respective mean total costs overlap ( (Table 3) .
DISCUSSION
In this emerging era of accountable care, organizations will be incentivized to reduce readmissions, achieve better health outcomes, and reduce health care utilization and costs. Traditionally, practitioners exhaust medical interventions, including pharmacotherapy, to improve disease severity with the expectation that costs will consequently decrease. These interventions are performed with little to no data regarding the extent to which patients are adherent to the treatment. Therefore, a significant gap in care and our understanding of the factors that influence health care costs persists. Data from this study demonstrate that medication nonadherence is related to significant increases in health care costs after controlling for the impact of disease severity. Specifically, patients with increasing nonadherence over time incur more than a 3-fold increase in health care costs compared with patients who are consistently adherent over time. In addition, patients who demonstrate improvement in adherence over time incur approximately the same costs as those who are consistently adherent. This suggests that, in addition to leveraging prevention efforts to keep patients from becoming more nonadherent as treatment continues, treatment efforts aimed at modifying adherence behavior can potentially result in significant cost savings over time.
Many patient-and system-level prevention and intervention possibilities exist. Prevention efforts can focus on regular assessment of adherence and feedback to the patient and caregivers regarding how closely the patient has adhered to a treatment regimen. Moreover, assessment of contextual factors that might contribute to nonadherence, such as socioeconomic status and psychosocial issues, can provide the opportunity for delivery of adjunctive health care services targeting issues that can have wide ranging negative health effects. With regular monitoring of adherence (e.g., through pharmacy refill, electronic monitoring, etc.), early intervention can target nonadherence and correct it before significant long-term health and economic costs. Clinicbased interventions can be implemented as part of regular care. These interventions must be very focused because of the limited time available in clinic and, while strictly educational interventions have not been successful, [33] [34] [35] [36] [37] [38] use of tools such as personal action plans can help to identify self-management goals for patients. Behavioral intervention delivered through separate outpatient care is promising [39] [40] [41] ; however, the number of trained professionals able to deliver these interventions is limited. With the ubiquitous use of technology by patients, options for telemedicine and mobile health applications are readily available and can increase practitioners' ability to provide intervisit care to support better selfmanagement. Insurance reimbursement policies and professional licensure laws need to accommodate these capabilities. Finally, system interventions have the potential to produce widespread change. Implementation of procedures such as preclinic planning can allow practitioners to plan the medical visit and use adherence data for self-management intervention planning. Adoption of uniform assessment procedures across subspecialties within a hospital system standardizes the approach to adherence monitoring and can destigmatize the need for self-management support. Furthermore, the current approach to health care reform itself has the potential to improve adherence through increased pressure on organizations to provide better care within a more restrictive cost structure. In this study, we used an objective assessment of nonadherence using pharmacy refill records to compute MPR. In addition, our use of a retrospective longitudinal design is a methodological strength with regard to adherence data, as this approach precluded the likelihood of patients' social desirability response, which is common with prospective monitoring of adherence. Furthermore, our statistical approach using LCGMM provided a unique longitudinal examination of the relationship between nonadherence and health care charges data while concurrently controlling for disease activity. This allowed us to identify groups of patients with similar longitudinal nonadherence patterns, thus creating categories of patients based on long-standing nonadherence behavior rather than a cross-sectional categorization that does not capture trends in this highly variable behavior. Additional population-based research is needed to better understand the demographic and disease characteristics of patients within each of these identified trajectories to aid in intervention development.
Our assessment methodology had 1 notable limitation. That is, disease activity assessments were not aligned exactly with nonadherence assessments. This concern is mitigated by the fact that disease activity in this sample was predominantly mild, and rapid progression of illness is uncommon in IBD. Thus, our use of the most recent disease activity assessment was appropriate. Nevertheless, future research should examine disease activity in regular intervals aligned with assessments of nonadherence. In addition, our aim for this study was restricted to examination of the costs associated with nonadherence to the 2 most common oral medication therapies for IBD. Although a smaller proportion of the sample received biologic therapy in addition to at least one of the oral medications of interest, the charges associated with biologics was not captured in our analyses. Thus, our results are specific to oral medication nonadherence and health care charges. Furthermore, our use of health care charge data carries important implications. Charges include direct institutional costs and indirects and profits, which often vary across hospitals. As a result, the dollar amounts presented in this article may not generalize to other institutions with differing billing practices or insurance contracts. However, as "costs" are typically derived using a cost-to-charge ratio, the direction and magnitude of the relationship between nonadherence and costs is likely to resemble the relationship demonstrated in this study. Future economic evaluations focused on determining the dollar amount saved by improving adherence in a particular population will require inclusion of cost data.
CONCLUSIONS
This study represents an important step in documenting the problem of nonadherence and the potential impact it has on health care costs. This has important ramifications for health care reform and how practitioners approach adherence assessment and intervention in routine care. Continued research is needed to determine the long-term impact of nonadherence on health care costs in other populations. More importantly, research investigating the costeffectiveness or cost offset of providing prevention and early intervention services to improve adherence in patients is a critical need. With sustained efforts to reduce nonadherence in chronic conditions, we may see concomitant reduction in health care costs.
